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Abstract: Diosgenin is a steroidal sapogenin found in plants such as Dioscorea nipponoca, Solanum incanum, Solanum  
xanthocarpum and Trigonella foenum graecum. Diosgenin, biologically active phytochemicals have been used for the treatment of 
various types of disorder such as leukemia, inflammation, hypercholesterolemia and cancer. It is also able to prevent bone loss to 
the same extent as that of oestrogen. It is a typical initial intermediate for synthesis of steroidal compounds, oral contraceptives and 
sex hormones. Dioscorea, Costus and Trigonella are mainly used for the production of diosgenin. On the basis of literature survey it 
divulges that diosgenin has very impressive pharmacological profile and could be used as a medicine for the treatment of  
different types of disorders in the future. Thus, the present work aims to provide collective information in concern with its  
pharmacological activity and phytoanalytical techniques. This review will be beneficial to researches for the development of an 
alternative method for the treatment of innumerable diseases from diosgenin. 
Keywords: analytical techniques, cancer, diosgenin, pharmacological activity, plant source, seperation techniques
Introduction 
Diosgenin (25R-spirost-5-en-3β-ol) (Figure 1) is a hydroly-
sate of dioscin found in the rootstock of yam (Dioscorea) and 
exists widely in the natural plant in the form of glucoside.1 It is 
a steroidal sapogenin found in various plants such as  
Dioscorea nipponoca Makino, Smilax china Linn, Smilax 
bockii Warb, Solanum incanum, Solanum xanthocarpum, 
Costus speciosus and Trigonella foenum graecum.2,3 It is a 
biologically active phytochemicals responsible for various 
type of action in the plant including functional food.1 It acts as 
a typical initial intermediate for the synthesis of steroid and 
contraceptive. However, it is also used in the form of medicine 
for the treatment of disease like leukemia, hypercholesterolemia,
climacteric syndrome and colon cancer.4 It is used as initial 
material for synthesis of oral contraceptives, sex hormones and 
other steroidal compounds.1 In plants it is found in the form of 
steroidal saponins. Due to its high steroidal saponins content, 
Dioscorea zingiberensis (C.H. Wright) is used in the China for 
the production of diosgenin. Acid hydrolysis of the raw herb is 
the traditional method of diosgenin production where sugar 
chains of steroidal saponins present in the herb are hydrolyzed 
to yield diosgenin.5 Diosgenin has been proven for the  
usefulness in the maintenance of healthy blood cholesterol 
levels along with the production of dehydroepiandrosterone. 
Sustained delivery of diosgenin has been able to significantly 
prevent bone loss.6 On the basis of the literature search of  
diosgenin, it was found that it had very impressive  
pharmacological profile and could be used as an alternative 
medicine to treat disparate disorders. Thus, the information 
summarized in this review will be helpful to the researchers in 
the field of natural product. 
 
1 Pharmacological Activity 
1.1 Effect of Diosgenin against Microorganism 
Diosgenin were investigated for its antimicrobial activity 
against the human pathogenic yeasts Candida albicans, C. 
glabrata and C. tropicalis and found to shown weak  
antimicrobial activity against all the tested organism.7 
 
1.2 Effect of Diosgenin against Virus 
Effect of diosgenin on hepatitis C virus (HCV) replication 
were evaluated and found to inhibit HCV replication at low 
micromolar concentrations. However, the levels of viral RNA 
and viral proteins are also significantly reduced.8  
*To whom correspondence should be addressed. E-mail: 
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1.3 Effect of Diosgenin on Blood System 
Anti-thrombosis effect of diosgenin was investigated using 
an inferior vena cava ligation thrombosis rat model and  
pulmonary thrombosis mice model both in vitro and in vivo, 
which resulted with inhibited platelet aggregation, thrombosis 
and prolonged activated partial thromboplastin time (APTT), 
prothrombin time (PT) and thrombin time (TT) in rats in a 
dose-dependent manner. Bleeding time, clotting time is also 
prolonged along with increased protection rate in mice which 
revealed it have anti-thrombosis activity.9 
 
1.4 Effect of Diosgenin on CNS 
The action of diosgenin on ion currents in human cortical 
neurons (HCN-1A) was investigated and the enhanced BK 
(Ca)-channel activity was also noted. However, in inside-out 
patches, diosgenin applied to the intracellular surface showed 
no effect on BK (Ca)-channel activity. It also elevated  
intracellular Ca2+ in HCN-1A cells. Western blotting revealed 
the presence of the alpha-subunit of BK (Ca)-channels in these 
cells. Functional activity of cortical neurons may be affected 
by diosgenin on these channels.10 In another study, diosgenin 
showed significant acetylcholinesterase (AchE) inhibitory 
activity.11 
 
1.5 Effect of Diosgenin on Calcium Homeostatic System 
Investigation on effect of diosgenin in osteoporosis induce 
female rats by ovariectomy suggest that bone loss after  
ovariectomy can be significantly reduced by supplementation 
with sustained levels diosgenin without jeopardizing other 
body organs.12 Diosgenin up-regulates VEGF-A and promotes 
angiogenesis in preosteoblast-like cells by a hypoxia-inducible 
factor-1alpha-dependent mechanism involving the activation 
of src kinase, p38 MAPK, and Akt signaling pathways via 
estrogen receptor.13 Effect of diosgenin on the osteogenesis of 
murine MC3T3-E1 osteoblastic cells was investigated.  
Enhanced bone formation by stimulating the synthesis and 
secretion of Type 1 collagen and ALP and bone marker  
proteins Runx2 and osteopontin expression was observed. The 
increased levels of these marker proteins can increase the  
formation of calcium deposition within the ECM thereby  
increasing bone formation.14 
 
1.6 Effect of Diosgenin on Cardiovascular System 
Many investigations have shown that, diosgenin can  
significantly reduce the levels of plasma total cholesterol TC 
and LDL-cholesterol and increase the ratio of HDL-cholesterol 
to TC by suppressing cholesterol absorption and increasing 
cholesterol secretion.2 Diosgenin as vasorelaxant in superior 
mesenteric rings were investigated using phenylephrine as a 
standard and found that it showed concentration-dependent 
relaxations. A mesenteric endothelial cell loaded with FURA-2 
diosgenin has the potential of increasing intracellular calcium 
concentrations, which was significantly decreased by atropine. 
In addition, diosgenin also increased nitric oxide (NO)  
levels.15 
Effect of diosgenin as vasodilator using porcine resistance 
left anterior descending coronary artery was investigated and 
found that it caused an acute endothelium-independent  
coronary artery relaxation via protein kinase G signaling  
cascade and an activation of BK (Ca) channel of arterial 
smooth muscle cells.16 Effects of diosgenin on smooth muscle 
cell contraction and calcium signaling were investigated in the 
isolated mouse aorta using wire myography and confocal mi-
croscopy. Significant blocking of receptor-mediated calcium 
signals and smooth muscle contraction in the isolated aorta 
were observed, implying a potential therapeutic value for  
diosgenin in vascular disorders.17 
 
1.7 Effect of Diosgenin on Blood Glucose System 
The effects of diosgenin on intestinal disaccharidases and 
some renal enzymes in diabetic rats were investigated for 3 
weeks. Diosgenin supplementation significantly decreased 
lactase and maltase activities compared to the diabetic control 
group. It also significantly decrease the activity of the trans-
aminases compared to the normal and diabetic control groups. 
Figure 1.  Chemical structure and overview of diosgenin 
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Diosgenin demonstrated hypoglycemic properties, which are 
beneficial in diabetes by reducing intestinal disaccharidases 
activities.18 Effects of diosgenin on fasting blood glucose and 
intestinal amylase and ATPases in streptozotocin-induced  
diabetic rats were studied. There was a significant increase in 
the activity of alpha-amylase in the proximal region of the 
small intestinal mucosa of diabetic rats treated with diosgenin. 
In fasting blood glucose, reduced Na+-K+-ATPase activity, 
Ca2+ ATPase activity in proximal region compared to the  
diabetic control was also found.19 Effects of diosgenin on  
enzyme level were investigated. Plasma glucose and glucose-
6-phosphatase level decreased significantly in diabetic rats fed 
with diosgenin as compared to the diabetic control. The activi-
ties of ATP-citrate lyase, pyruvate kinase and glucose-6-
phosphate dehydrogenase were significantly reduced in the 
liver of diabetic rats compared to normal control.20 Diosgenin 
inhibited glucose-uptake in the test along with the inhibition of 
glucagon-induced HGPa activity in the tested model.21 
 
1.8 Effect of Diosgenin on Immune System 
Suppressive effect of diosgenin on the intestinal T helper 
(Th) 2 responses is associated with an enhancement of the 
regulatory T-cell immunity. Administration of diosgenin 
markedly attenuated the intestinal expression of interleukin 
(IL)-4 and GATA3 in Ovalbumin (OVA)-sensitized BALB/c 
mice. These results suggest that the suppressive effect of  
diosgenin on allergen-induced intestinal Th2 responses is 
closely associated with an up-regulation of the regulatory  
T-cell immunity in the inflammatory site.22 Effect of diosgenin 
on humoral immunity was investigated in ovalbumin (OVA)-
sensitized and challenged BALB/c mice for 34 days. The  
production of OVA-specific serum IgG2a was significantly 
enhanced by diosgenin treatment. In parallel with the  
enhancement of IgG2a, OVA-induced IFN-gamma secretion 
and mRNA expression were markedly elevated in splenocytes 
of diosgenin-treated mice. Furthermore, the expression of  
T-bet, but not of GATA-3, in splenocytes was up-regulated by 
diosgenin administration.23 The effects of three diosgenyl  
saponins on the immuno stimulating activity in relation to 
phagocytosis, respiratory burst and nitric oxide production in 
mouse macrophage cells RAW 264.7 have been investigated. 
Results showed that diosgenyl saponins significantly enhanced 
phagocytic activity that increased with the concentration of 
saponins to reach a maximum, and then tended to decrease 
with higher concentrations.24 
Diosgenin were screened for anti-allergic activities using 
RBL-2H3 cells, the aglycone was found to possess higher 
activity than the diglucosylated molecule; whereas substitution 
with rhamnoglucosides apparently results in loss of activity. 
Furthermore, effects of dioscorealide A, dioscorealide B and 
dioscoreanone on antigen-induced release of TNF-alpha and 
IL-4 in the late phase reaction were also examined.25 Plant 
steroid diosgenin causes an inhibition of the growth of  
fibroblast-like synoviocytes from human rheumatoid arthritis, 
with apoptosis induction associated with cyclooxygenase-2 
(COX-2) up-regulation. These findings suggest that the 
proapoptotic effect of diosgenin is associated with overexpres-
sion of COX-2 correlated with overproduction of endogenous 
prostaglandin E2.26 Effect of incessant deliver diosgenin to 
adult ovariectomized female rats for 45 days and follow 
changes in body weight, organ weight and histopathological 
changes in the adrenal gland were investigated. The results 
indicated that ovariectomized animals had a significant  
increase in body weight and spleen weights. Slight increases in 
wet adrenal weights were observed in the ovariectomized 
group compared to the control animals.27 
 
1.9 Effect of Diosgenin on Lipid System 
Hypolipidemic effects of diosgenin on rats fed with high 
cholesterol and high fat diet for 6 weeks was investigated. 
Diosgenin treatment increased lipoprotein lipase (LPL),  
hepaticlipase (HL), superoxide dismutase (SOD), glutathione 
peroxidase (GSH-PX) and nitric oxide synthase NOS activities, 
thus attenuated oxygen free radicals, decreased malondialde-
hyde (MDA), TC, TG and LDL-C levels in hyperlipidemic 
rats.28 Hypolipidemic and antioxidative effect of diosgenin on 
rats fed with a high-cholesterol diet supplemented for 6 weeks 
were investigated. It showed a decrease in the plasma and  
hepatic total cholesterol levels, but increased the plasma  
high-density lipoprotein (HDL) cholesterol level. Furthermore, 
diosgenin feeding enhanced the resistance to lymphocyte DNA 
damage caused by an oxidant challenge with H2O2.29 Effects of 
diosgenin-induced cholesterol hypersecretion on Abcg5/g8 
expression in wild-type mice were investigated. Diosgenin did 
not stimulate biliary cholesterol secretion in mice deficient for 
Abcg8. Diosgenin feeding increased hepatic expression of 
genes involved in cholesterol synthesis as well as genes  
encoding for several cytochrome P450s.30 
The effect of diosgenin, ethinyl estradiol and this  
co-administration on changes of lipoprotein metabolism and 
expression of hepatic genes those are important for cholesterol 
metabolism including the recently identified abcg5 and abcg8 
in male Wistar rats was invesigated. Diosgenin-feeding  
induced the hepatic abcg5/abcg8 expressions and biliary  
cholesterol secretion.31 Dioscin and its aglycone, diosgenin, 
both suppressed the time-dependent increase of blood  
triacylglycerol level when orally injected with corn oil to mice, 
suggesting their inhibitory potential against fat absorption.32 
Diosgenin showed significantly therapeutic and preventive 
effect on hypercholesterolemia in mice. The serum total  
cholesterol level was decreased when rats were pre-treated 
with diosgenin.33 Diosgenin inhibited the accumulation of TG 
and the expression of lipogenic genes in HepG2 cells.  
Moreover, diosgenin inhibited the transactivation of liver-X-
receptor-α, as measured using a luciferase assay system and by 
gel mobility shift assay.34 
 
1.10 Effect of Diosgenin on Oxidative System 
Effect of diosgenin supplementation on antioxidative  
enzyme activities were investigated and found to be affected 
with diosgenin supplementation. Total superoxide dismutase 
(SOD) in the plasma and liver, glutathione peroxidase (GSH-
Px) in erythrocytes, and catalase (CAT) in erythrocytes and 
liver were significantly increased in the diosgenin group. The 
expression of antioxidative enzymes was up-regulated by  
diosgenin, the expression of GSH-Px being the highest in the 
diosgenin group.35 Effect of diosgenin on the senescent mice 
induced by d-galactose for sixth week was investigated. It 
showed increased activities of superoxide dismutase (SOD) 
and glutathione peroxidase (GSH-Px) and decreased 
malondialdehyde (MDA) level in the brain of d-galactose 
treated mice.36 Effect of diosgenin for a period of 35 days on 
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lysosomal hydrolases, membrane-bound enzymes, and  
electrolytes during isoproterenol induced myocardial necrosis 
in rats was investigated. Diosgenin pretreated groups showed 
significant decrease in CK-MB, lipid peroxidation, and  
lysosomal hydrolases activity. Diosgenin pretreatment  
reversed the membrane-bound enzymes activity and thereby 
maintained the normal electrolyte concentration, suggesting 
the protective action in isoproterenol induced myocardial  
infarction.37 
 
1.11 Effect of Diosgenin on Inflamatory System 
The effect of diosgenin on the expression of adhesion  
molecules induced by TNF-α in cultured mouse VSMC cell 
line, MOVAS-1 was investigated, and found that diosgenin 
inhibits the adhesive capacity of VSMC and the TNF-α-
mediated induction of ICAM-1 and VCAM-1 in VSMC by 
inhibiting the MAPK/Akt/NF-κB signaling pathway and ROS 
production explaining the ability of diosgenin to suppress  
inflammation within the atherosclerotic lesion and modulate 
immune response.38 Effects of diosgenin on the production of 
inflammatory mediators in lipopolysaccharide (LPS)/interferon
gamma (IFN-gamma)-activated murine macrophage were  
investigated. Pretreatment with diosgenin resulted in the  
inhibition of NO production and inducible nitric oxide  
synthase (iNOS) protein and mRNA expression in a  
concentration-dependent manner.39 
Effect of diosgenin on the inflammatory changes in the  
interaction between adipocytes and macrophages was  
investigated. A coculture of 3T3-L1 adipocytes and RAW 264 
macrophages markedly enhanced the production of tumor  
necrosis factor-alpha, monocyte chemoattractant protein-1, 
and nitric oxide compared with the sum of their single cultures; 
however, treatment with diosgenin inhibited the production of 
these proinflammatory mediators. Diosgenin also suppressed 
the inflammation in RAW 264 macrophages that was induced 
by the conditioned medium derived from 3T3-L1 adipocytes.40 
Effect of diosgening on modulating food allergy was  
investigated in BALB/c mice. Diosgenin demonstrated a  
suppressive effect on the intestinal inflammation, including the 
occurrence of diarrhea, the infiltration and degranulation of 
mast cells, and the presence of mucin-containing goblet cells 
in the duodenum. Furthermore, the serum production of OVA-
specific IgE, and the total IgE was suppressed.41 
 
1.12 Effect of Diosgenin on Reproductive System 
An effect of diosgenin on the calpain isoform expression in 
ovariectomized rats was investigated. To the contrary, no  
significant difference in the expression of mu- and m-calpain 
mRNAs among the different diosgenin dosage groups was 
found. Decreased expression of mu- or m-calpain was  
observed in the ovariectomized group compared with the  
normal controls.42 Effect of diosgenin on stimulated growth of 
mammary epithelium for 15 days was investigated with a  
parameter of increase in DNA content, increase in number of 
ducts and appearance of terminal endbuds in this study, and 
the observation was a significant increase in the mammary 
development scores. Concomitant treatment of estrogen and 
diosgenin showed augmentation of estrogenic effect of  
diosgenin especially at the higher dose level.43 
 
1.13 Effect of Diosgenin on Cancer 
Effects of diosgenin on cell proliferation induced by IGF-1 
in primary human thyroid cells were investigated. Cell  
viability by MTT and cell proliferation was tested by EdU 
assay, where as cell cycle analysis was performed by FACS. 
This study revealed that diosgenin inhibited cell proliferation, 
caused G 0/G (1) arrest, and could inhibit cell proliferation 
induced by IGF-1 in primary human thyroid cells.44 Diosgenin 
inhibited migration and invasion of PC-3 cells by reducing 
matrix metalloproteinase expression. It also inhibited extracel-
lular signal regulating kinase, Jun N-terminal kinase and  
phosphatidylinositide-3 kinase /Akt signaling pathways as well 
as NF-κB activity. These findings reveal new therapeutic  
potential for diosgenin in anti-metastatic therapy.45 
Effect of diosgenin on TRAIL-induced apoptosis in HT-29 
cells was investigated and found that diosgenin sensitizes  
HT-29 cells to TRAIL-induced apoptosis. Diosgenin-induced 
p38 MAPK pathway activation and subsequent DR5 over  
expression cardinally involve this underlying mechanisms 
sensitization.46 The implication of COX-2 and 5-LOX in  
diosgenin-induced apoptosis were investigated and results 
demonstrate how difficult it is to assess the correlation  
between the apoptotic signaling pathway of diosgenin and 
arachidonic acid metabolism with certitude.47 In another study 
it was found that kinases including Src, Tor, Akt, CREB, RSK 
and Chk2 may be implicated in signaling of subsequent  
apoptosis of mature megakaryocytes after diosgenin-induced 
differentiation of HEL cells.48 In another study, no significant 
toxicity was seen in the normal breast epithelial cells (MCF-
10A) following treatment with diosgenin. Additionally, in vivo 
tumor studies indicate diosgenin significantly inhibits tumor 
growth in both MCF-7 and MDA-231 xenografts in nude 
mice.49 
Implication of cyclooxygenase-2 (COX-2) and thromboxane 
synthase (TxS) in diosgenin-induced megakaryocytic  
differentiation in HEL (human erythroleukemia) cells were 
investigated in another study.50 Diosgenin inhibited the  
reduction of Akt and GSK 3beta phosphorylation induced by 
LY294, 002, a PI3K inhibitor. Result revealed that production 
levels of MITF (microphthalmia-associated transcription  
factor) and tyrosinase were increased by diosgenin. Study 
showed that diosgenin inhibits melanogenesis by activating the 
PI3K pathway, and also suggests that diosgenin may be an 
effective inhibitor of hyperpigmentation.51 Food saponin,  
diosgenin is a potent inhibitor of HCT-116 human colon  
carcinoma cells by growth inhibition and induction of apoptosis.
Importantly, result identifies that the growth suppressive or 
apoptotic activity of diosgenin may involve cholesterol home-
ostasis.52 Combined association implicating a MEK inhibitor 
(U0126) and diosgenin is the most effective in inducing very 
strong apoptosis with down-regulation of COX-2 expression 
and activity in human RA FLS.53 Diosgenin induced megakar-
yocytic differentiation of HEL cells through a combined acti-
vation of ERK and inhibition of the p38 MAPK pathways. 
Inhibition of ERK activation by a MEK inhibitor abrogated 
diosgenin-induced differentiation. Afterwards, differentiated 
cells showed a marked inhibition of expression of survival 
factors NF-kappaB, Akt and Bcl-xL and activation of caspase-3
together with PARP cleavage leading to apoptotic death of 
diosgenin-differentiated cells.54 
Diosgenin decreased DNA binding of NF-kappaB in K562 
and HEL cells after 48-h diosgenin treatment. Diosgenin-
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induced apoptosis was associated with cyclo-oxygenase-2 
(COX-2) up-regulation in HEL cells but not in K562 cells 
which are COX-2 deficient. Furthermore, diosgenin inhibited 
extracellular signal-regulated kinase (ERK) activation only in 
HEL cells. However, diosgenin activated p38 MAPK in both 
cell lines and activated c-jun NH2-terminal kinases (JNKs) 
only in HEL cells. Results suggest that inhibition of NF-
kappaB nuclear binding and p38 MAPK activation are  
involved in the diosgenin-mediated signal cascades in K562 
cells for inducing/regulating DNA fragmentation.55 Diosgenin 
can effectively inhibit the viability and proliferation of the 
breast cancer cells.56 Diosgenin caused G2/M arrest  
independently of p53. The levels of cyclin B1 and 
p21Cip1/Waf1 were decreased, whereas cdc2 levels were  
increased on the basis of cell cycle analysis. Diosgenin inhibits 
K562 cell proliferation via cell cycle G2/M arrest and apoptosis,
with disruption of Ca2+ homeostasis and mitochondrial  
dysfunction playing vital roles.57 
Dietary diosgenin inhibited total colonic aberrant crypt foci 
(ACF) and multicrypt foci formation in a dose-dependent 
manner. Diosgenin inhibits cell growth and induces apoptosis 
in the HT-29 human colon cancer cell line in a dose-dependent 
manner.58 Diosgenin-induced apoptosis is caspase-3 dependent 
with a fall of mitochondrial membrane potential, nuclear  
localization of AIF and poly (ADP-ribose) polymerase  
cleavage. Diosgenin treatment also induces p53 activation and 
cell cycle arrest in the different cell lines studied.59 Diosgenin 
inhibited S-180, HepA, U 14 mice transplant tumor, the inhibit 
rates being 30%-50%, but it did not inhibit the EAC mice 
transplant tumor. In vitro, diosgenin inhibited L929, HeLa, 
MCF cell growth, but it did not significantly affect A375-S2 
cells. Diosgenin had an obvious antitumor activity on S-180, 
HepA, U14 transplant mice in vivo and L929, HeLa, MCF 
cells in vitro.60 Diosgenin treatment caused an inhibition of 
1547 cell growth with a cycle arrest in G1 phase and apoptosis 
induction. Moreover, it was also found a correlation between 
p53, p21 mRNA expression and nuclear factor kappaB  
activation and observed a time-dependent increase in PGE2 
synthesis after diosgenin treatment.61 Diosgenin inhibits  
receptor-activated nuclear factor-kappaB ligand-induced  
osteoclastogenesis, suppresses tumor necrosis factor TNF-
induced invasion, and blocks the proliferation of tumor cells, 
all activities known to be regulated by NF-kappaB. The results 
suggest that diosgenin suppresses proliferation, inhibits inva-
sion, and suppresses osteoclastogenesis through inhibition of 
NF-kappaB-regulated gene expression and enhances apoptosis 
induced by cytokines and chemotherapeutic agents.62 
 
1.14 Effect of Diosgenin on Metabolic Process 
The effect of diosgenin on faecal minerals and intestinal  
lipids in streptozotocin-induced diabetic rats was studied for 
three weeks. Diosgenin did not altered faecal magnesium,  
calcium, and zinc excretion but significantly decreased faecal 
sodium and potassium excretion. It significantly decreased 
intestinal lipid towards normal, faecal lipids excreted was  
significantly higher in diabetic rats fed diosgenin.63 Effects of 
dietary diosgenin on indomethacin induced intestinal  
inflammation and alterations in bile secretion in rats were  
investigated. Diosgenin pretreatment significantly inhibited 
weight and food intake decreases and intestinal inflammation. 
Diosgenin significantly increased biliary cholesterol output 
and prevented the decreases in bile flow, bile acid output, and 
biliary alpha-muricholic acid and the increases in biliary  
hyodeoxycholic acid, deoxycholic acid, and hydrophobicity 
index of bile.64 
Effect of diosgenin on bile secretion, focusing on canalicular
membrane composition, membrane fluidity, transporter  
expression, and transporter activity were invetigated. Bile flow, 
especially bile acid-independent fraction, was increased  
significantly by diosgenin. Biliary output of Ch and total  
glutathione were significantly increased by diosgenin. CMV 
fluidity and Mrp2 expression were increased by diosgenin. 
The increase of CMV fluidity and Mrp2 suggests that the 
choleretic action of diosgenin was based upon both the direct 
stimulation of transporter expression and indirect transporter 
activation by an increase of membrane fluidity.65 Biliary  
cholesterol output in rats was stimulated over 3-fold by  
feeding diosgenin for 5 days, whereas biliary outputs of  
phospholipid and bile salts were not changed by diosgenin 
feeding. Isolating and perfusing the liver without bile salts 
resulted in a rapid and substantial decrease in biliary bile salt 
output; bile salt depletion abolished the diosgenin-induced 
increment in biliary cholesterol output, showing that the  
diosgenin-elevated biliary cholesterol output was bile-salt-
dependent.66 
Diosgenin and beta-sitosterol were administered to CRJ/CD 
male mice for 15 days, the changes in bile acid metabolism 
was examined. This resulted with some differences between 
diosgenin and beta-sitosterol in their effects on diet intake, 
liver weight, and plasma cholesterol level. Most of the  
increase in fecal excretion of cholesterol occurred 2 days after 
the start of feeding of phytosterols and gradually declined 
thereafter, but the levels on day 15 were nevertheless higher 
than those in the control mice.67 Effect of diosgenin in biliary 
secretion and intestinal absorption of cholesterol in diosgenin-
stimulated fecal cholesterol excretion in wild type and 
NPC1L1-knockout (L1KO) mice were investigated. Fecal 
cholesterol excretion increased in diosgenin-fed WT and 
L1KO mice. In an in vitro assay, diosgenin was unable to 
block NPC1L1-dependent cholesterol uptake.68 
 
2 Extraction Techniques of Diosgenin 
Because of its biological activities, numerous researches on 
separation and purification of diosgenin from herb have widely
been explored through the traditional separation techniques 
such as liquid-liquid extraction (LLE) and solid-phase  
extraction (SPE), which can meet the separating requirements 
of purity.4 Methods of extraction of diosgenin from Dioscorea 
zingiberensis, C.H. Wright include direct acid hydrolysis, 
spontaneous fermentation, and supercritical CO2 extraction. 
Recently, some researchers used a single enzyme (such as 
cellulase and theamylase) combined with acid hydrolysis to 
treat Chinese yam (Dioscorea opposita Thunb) material, 
demonstrating that about 70% diosgenin can be extracted from 
the material. However, the activity of enzyme gradually  
reduces owing to the change of catalysis environment, so that 
the catalysis efficiency of enzyme will also reduce.1 A focused 
microwave-assisted extraction method was developed for the 
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3 Analytical Techniques of Diosgenin 
Gas chromatography-mass spectrometry (GC-MS) method 
to determine the content of diosgenin in rats has been reported. 
For quantification; a single-ion monitoring (SIM) mode was 
used; the limit of quantification (LOQ) was 13 ng/mL, and 
separation time was > 18 min.2 A sensitive and specific  
electrospray ionization liquid chromatography-tandem mass 
spectrometry method was developed to detect diosgenin in the 
plasma of normal and hyperlipidemic rats. This technique can 
be used successfully to study pharmacokinetics in rats after 
oral administration of diosgenin and would be beneficial for 
the clinical use of diosgenin.70 
 
4 Discussion 
Though, advances have been made in the understanding of 
the mechanism of action of various herbs, but many questions 
remain unanswered. For the past few years there has been an 
exponential growth in the field of herbal medicine and these 
drugs are gaining popularity both in developing and developed 
countries because of their natural origin and less side effects. 
Many traditional medicines in use are derived from medicinal 
plants, minerals and organic matter. A number of medicinal 
plants, traditionally used for over 1000 years named rasayana, 
having their existence in herbal preparations of Indian  
traditional health care systems. The World Health Organization
(WHO) has listed 21,000 plants, which are used for medicinal 
purposes around the world. Among these 2500 species in India, 
150 species are used commercially on a fairly large scale.71–73 
Because many medicinal plants constitute a rich source of 
bioactive chemicals that are largely free from adverse effects 
and have excellent pharmacological actions and could lead to 
the development of new classes of possibly safer agents for the 
treatment of disease. Plants have always been an exemplary 
source of drugs and many of the currently available drugs have 
been derived directly or indirectly from them.74,75 
Due to economic constraints, providing modern medical 
healthcare in developing countries is still a far-reaching goal. 
The most commonly used drugs of modern medicine such as 
aspirin, anti-malarial, anti-cancer; digitalis, etc. have originated
from plant sources.76 Despite the great interest in the  
development of new drugs to prevent the burden of  
complications associated with this disease and raised interest 
in the scientific community to evaluate either raw or isolated 
natural products in experimental studies, few of them was tested
in humans. Based on the available data it was concluded that 
this bioactive compound have various type of activity and 
beneficial effect against microorganism, inflammation,  
cardiovascular disease, blood disorder, cerebral disorder,  
immune system, oxidative stress, reproductive and cancer 
chemotherapy. However their specific effects on cancer  
disease give valuable role for the treatment of various type of 
cancerous disease. Although phytotherapy continues to be 
used in several countries, few plants have received scientific or 
medical scrutinity.  
Several medicinal plants have been used as dietary adjunct 
and in the treatment of numerous diseases without proper 
knowledge of their function. Only a few herbs and bioactive 
chemical moiety have attracted the interest of scientists and 
have been put forward for investigations. However, the  
pharmacologic actions of these compounds need to be evaluated
in studies involving humans to justify the use of these plants or 
their active principles for the treatment of various disorders. 
Therefore, there is a need of more well-documented clinical 
trials and more laboratory work to justify their pharmacological
actions and toxicity for safe and effective treatment. Diosgenin 
which, as per, mentioned above may have all these actions and 
could prove to be promising in the treatment of various  
complications especially against cancer in the near future. 
In conclusion, the review provides relevant information  
regarding the pharmacological aspects of diosgenin. The  
review provides the database of the pharmacological activity 
of diosgenin, its extraction and analytical procedure for the 
determination which can be useful for the researcher who 
wants to explore the hidden potential of this phytoconstituents. 
The collective information summarized in the review will act 
as an important segment for development of effective  
medicines for the treatment of diseases like cancer. 
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